What Intuitive Surgical (ISRG) Investors Need to Know Today

Large-cap health care company Intuitive Surgical has moved 0.8% this afternoon, reaching $293.92 per share. In contrast, the average analyst target price for the stock is $327.5.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company is based in the United States.

What to Consider if You Are Thinking of Buying Intuitive Surgical:

  • Intuitive Surgical has moved 12.0% over the last year.

  • ISRG has a forward P/E ratio of 45.7 based on its EPS guidance of 6.43.

  • Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 6.1%.

  • The company has a price to earnings growth (PEG) ratio of 3.33.

  • Its Price to Book (P/B) ratio is 8.25

Intuitive Surgical Has Irregular Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 2,023,400 767,900 1,255,500 31.0
2022 1,490,800 532,400 958,400 -45.23
2021 2,089,400 339,500 1,749,900 53.06
2020 1,484,800 341,500 1,143,300 -2.5
2019 1,598,200 425,600 1,172,600 19.39
2018 1,169,600 187,400 982,200

Intuitive Surgical's free cash flows have a decent average of $1.21 Billion over the last 6 years, but they are highly variable since their coefficient of variability is 402.3%. The compounded average growth rate over this period is 4.2%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.